Damora Therapeutics, Inc. is trading 5.4% down at $21.12 today, extending a multi-day slide from recent closes above $24 amid broader volatility in the biotechnology sector.
- There are no fresh company-specific headlines or SEC filings to account for the move; the most recent news was a routine inducement stock option grant announced on June 1.
- In the absence of direct catalysts, the downward pressure appears to reflect ongoing risk-off sentiment currently affecting smaller-cap biotech names.